Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease

Clinical Cardiology

Volumn 19, Issue 9, 1996, Pages 683-689

  Rackley, Charles E ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; coronary; HMG CoA reductase; monotherapy; regression; secondary prevention

Indexed keywords

COLESTIPOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; WARFARIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; HUMAN; LIPID BLOOD LEVEL; MORTALITY; RECURRENT DISEASE; REVIEW;

EID: 0029818771     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190903     Document Type: Review

References (33)

1. Talley JD, Hurst JW, King SB III, Douglas JS Jr, Roubin GS, Gruentzig AR, Anderson HV, Weintraub WS: Clinical outcome 5 years after attempted percutaneous transluminal coronary angioplasty in 427 patients. Circulation 77, 820-829 (1988)
2. The VA Coronary Artery Bypass Surgery Cooperative Study Group: Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation 86, 121-130 (1992)
3. Superko HR, Krauss RM: Coronary artery disease regression: Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 90, 1056-1069 (1994)
4. Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 73, 3D-11D (1994)
5. Brown BG, Zhao X-Q, Sacco DE, Albers JJ: Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87, 1781-1791 (1993)
6. Herd JA, West MS, Ballantyne C, Farmer J, Gotto AM Jr: Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am J Cardiol 73, 42D-49D (1994)
7. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bissen BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323, 1289-1298 (1990)
8. Blankenhom DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group: Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119, 969-976 (1993)
9. Waters W, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, and the CCAIT Study Group: Effects of monotherapy with an HMG Co-A reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89, 959-968 (1994)
10. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 90, 1679-1687 (1994)
11. MAAS Investigators: Effect of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study (MAAS). Lancet 344, 633-638 (1994)
12. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994)
13. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, McGovem ME, for the PLAC I Investigators: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in athersclerotic progression and clinical events. J Am Coll Cardiol 26, 1133-1139 (1995)
14. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AE, Jansen H, Boerma GJM, van Rappard FM, Lie KI on behalf of the REGRESS study group: Effects of lipid lowering by pravastatin in progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated cholesterol levels: The Regression Growth Evaluation Study (REGRESS). Circulation 91, 2528-2540 (1995)
15. The Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/1 (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 72, 1031-1037 (1993)
16. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC II). Am J Cardiol 75, 455-459 (1995)
17. Rossouw J: Workshop on stabilization and regression of atherosclerosis. Newspaper of Cardiology Aug, 1 (1991)
18. Pearson TA, Marx HJ: The rapid reduction in cardiac events with lipid-lowering therapy: Mechanisms and implications. Am J Cardiol 72, 1072-1073 (1993)
19. Philbin EF, Pearson TA: How does lipid-lowering therapy rapidly reduce ischemic events? J Myocard Ischem 6, 13-18 (1994)
20. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE: Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 68, 1425-1430 (1991)
21. Kuhn FE, Mohler ER, Rackley CE: Cholesterol and lipoproteins: Beyond atherogenesis. Clin Cardiol 15, 883-890 (1992)
22. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332, 481-487 (1995)
23. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: Cholesterol-lowering therapy improves endothelial function in patients with coronary atherosclerosis. N Engl J Med 332, 488-493 (1995)
24. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89, 2519-2524 (1994)
25. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320, 915-924 (1989)
26. Yala-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84, 1086-1095 (1989)
27. Lavy A, Brook GJ, Danker G, Amotz AB, Aviram M: Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 40, 794-799 (1991)
28. Cominacini L, Pastorino AM, Garbin U, Campagnola M, De Santis A, Davoli A, LoCascio V: Susceptibility to oxidation of LDL derived from hypercholesterolemic patients and its relation to preformed lipid hyperperoxides in native LDL. In Dietary Lipids, Anti-Oxidants and the Prevention of Atherosclerosis (Eds. Ursini F, Cadenas E). CLUEP, Padova, Italy (1993) 97-99
29. Lamb DJ, Wilkins GM, Leake DS: The oxidative modification of low-density lipoprotein by human lymphocytes. Atherosclerosis 92, 187-192 (1992)
30. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, Breall JA, Rackley CE: Autoantibody titers to oxidized low density lipoprotein in patients with coronary atherosclerosis. Am Heart J 131, 663-667 (1996)
31. LaCoste LL, Lam JYT, Hung J, Waters D: Pravachol decreases platelet thrombus formation in hypercholesterolemic coronary patients in conjunction with improvements in serum lipids. J Am Coll Cardiol Feb, 131A (1994)
32. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 269, 3015-3023 (1993)
33. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 344, 1182-1186 (1994)